BLCM Insider Trading Activity and SEC Form 4 Filings
BLCM insider trading summary
No open-market insider purchases or sales of Bellicum Pharmaceuticals, Inc (BLCM) have been reported on SEC Form 4 in the past 12 months.
Latest BLCM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 17, 2020 | Richard A. Fair | President and CEO | Buy | $20K (5,000 @ $4.00) |
| Sep 10, 2019 | Richard A. Fair | President and CEO | Buy | $50K (40,000 @ $1.25) |
| Aug 29, 2019 | Shane Ward | Sr. VP and General Counsel | Buy | $10K (8,000 @ $1.23) |
| Aug 21, 2019 | Richard A. Fair | President and CEO | Buy | $20K (20,000 @ $0.99) |
| Nov 9, 2018 | Jon P Stonehouse | Director | Buy | $46K (10,000 @ $4.56) |
| Sep 4, 2018 | David M. Spencer | Chief Technology Officer | Sell | $70K (10,000 @ $7.04) |
| Jul 18, 2018 | David M. Spencer | Chief Technology Officer | Sell | $305K (40,000 @ $7.63) |
| May 25, 2018 | Alan A Musso | CFO and Treasurer | Sell | $49K (6,206 @ $7.97) |
| Jan 19, 2018 | Julian Baker | 10% Owner | Sell | $202K (25,517 @ $7.91) |
| Jan 19, 2018 | Baker Bros. Advisors LP | 10% Owner | Sell | $2.1M (265,708 @ $7.91) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.